Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for tuberculosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Imaging of Possible Tuberculosis American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material is permitted for research, scientific and/or information purposes only. You may not modify (...) or create derivative works based on American College of Radiology material. No part of any material posted on the American College of Radiology Web site may be copied, downloaded, stored in a retrieval system, or redistributed for any other purpose without the expressed written permission of American College of Radiology. New 2016 ACR Appropriateness Criteria ® 1 Imaging of Possible Tuberculosis American College of Radiology ACR Appropriateness Criteria ® Imaging of Possible Tuberculosis Variant 1
Latent Tuberculosis Infection: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Asymptomatic adults at increased risk for infection The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk. B View the Clinical Summary in Population Asymptomatic adults at increased risk for infection Recommendation Screen for latent tuberculosis infection (LTBI). Grade: B Risk (...) Assessment Populations at increased risk for LTBI include persons who were born in, or are former residents of, countries with increased tuberculosis prevalence and persons who live in, or have lived in, high-risk congregate settings (eg, homeless shelters and correctional facilities). Local demographic patterns may vary across the United States; clinicians can consult their local or state health departments for more information about populations at risk in their community. Screening Tests Screening
Primary tuberculosis of palate Primary tuberculosis (TB) of the hard palate is very rare. A 74-year-old man was presented with 6-month history of dysphagia along with an irregular mass in the hard and soft palate. Magnetic resonance imaging (MRI) revealed thickened and increased signal intensity within hard and soft palate. Tissue biopsy showed focal caseating granulomatous-like lesion and the histochemical staining using Ziehl-Neelsen stain for acid-fast bacilli was positive. Positive
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. 26649984 2015 12 18 2015 12 17 1533-4406 373 25 2015 Dec 17 The New England journal of medicine N. Engl. J. Med. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. e29 10.1056/NEJMx150041 eng Published Erratum 2015 12 09 United States N Engl J Med 0255562 0028-4793 N Engl J Med. 2015 Nov 12;373(20):1986-8 26559594 Stuckia, David [corrected to Stucki, David] 2015 12 10 6 0 2015 12 10 6 0 2015
Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora There is an urgent need to discover and develop new drugs to combat Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) in humans. In recent years, there has been a renewed interest in the discovery of new anti-TB agents from natural sources. In the present investigation, molecular docking studies were carried out (...) on two ellagic acid derivatives, namely pteleoellagic acid (1) isolated from Ludwigia adscendens, and 3,3'-di-O-methyl ellagic acid 4-O-α-rhamnopyranoside (2) isolated from Trewia nudiflora, to investigate their binding to two enzymes involved in M. tuberculosis cell wall biogenesis, namely 2-trans-enoyl-ACP reductase (InhA) and β-ketoacyl-ACP reductase (MabA), and to pantothenate kinase (PanK type I) involved in the biosynthesis of coenzyme A, essential for the growth of M. tuberculosis.Molecular
Disseminated Tuberculosis in an Immunocompetent Patient: The Answer is in the Liver Tuberculosis, a chronic infectious disease caused by Mycobacterium tuberculosis, may invade all organs but mainly affect the lungs. We report a case of disseminated tuberculosis with hepatic, pericardial and pleural involvement and a review of the relevant literature. A 64-year-old Portuguese male was admitted with epigastric and right upper quadrant pain associated with low grade fever, fatigue, nausea (...) , anorexia, weight loss (6 kg) and mild jaundice. A chest X-ray showed cardiomegaly and a computed tomographic scan of the thorax and abdomen revealed a mild left pleural effusion, a thickened pericardium with signs of incipient calcification and hepatomegaly. The echocardiogram suggested the diagnosis of constrictive pericarditis. Liver biopsy revealed granulomatous lesions with central caseating necrosis. Tuberculosis is usually associated with atypical clinical manifestations. Imaging examination
Treatment of Tuberculosis. 26605929 2015 12 04 2016 11 26 1533-4406 373 22 2015 Nov 26 The New England journal of medicine N. Engl. J. Med. Treatment of Tuberculosis. 2149-60 10.1056/NEJMra1413919 Horsburgh C Robert CR Jr Barry Clifton E CE 3rd Lange Christoph C eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents AIM IM Adult Antitubercular Agents pharmacokinetics therapeutic use Child Humans Lung diagnostic imaging Mycobacterium tuberculosis (...) physiology Tomography, X-Ray Computed Tuberculosis diagnostic imaging drug therapy 2015 11 26 6 0 2015 11 26 6 0 2015 12 15 6 0 ppublish 26605929 10.1056/NEJMra1413919
Data for action: collection and use of local data to end tuberculosis. Accelerating progress in the fight against tuberculosis will require a drastic shift from a strategy focused on control to one focused on elimination. Successful disease elimination campaigns are characterised by locally tailored responses that are informed by appropriate data. To develop such a response to tuberculosis, we suggest a three-step process that includes improved collection and use of existing programmatic data (...) , collection of additional data (eg, geographic information, drug resistance, and risk factors) to inform tailored responses, and targeted collection of novel data (eg, sequencing data, targeted surveys, and contact investigations) to improve understanding of tuberculosis transmission dynamics. Development of a locally targeted response for tuberculosis will require substantial investment to reconfigure existing systems, coupled with additional empirical data to evaluate the effectiveness of specific
Stopping tuberculosis: a biosocial model for sustainable development. Tuberculosis transmission and progression are largely driven by social factors such as poor living conditions and poor nutrition. Increased standards of living and social approaches helped to decrease the burden of tuberculosis before the introduction of chemotherapy in the 1940s. Since then, management of tuberculosis has been largely biomedical. More funding for tuberculosis since 2000, coinciding with the Millennium (...) Development Goals, has yielded progress in tuberculosis mortality but smaller reductions in incidence, which continues to pose a risk to sustainable development, especially in poor and susceptible populations. These at-risk populations need accelerated progress to end tuberculosis as resolved by the World Health Assembly in 2015. Effectively addressing the worldwide tuberculosis burden will need not only enhancement of biomedical approaches but also rebuilding of the social approaches of the past
Latent Mycobacterium tuberculosis Infection. 26376149 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1179-80 10.1056/NEJMc1508223 Getahun Haileyesus H Chaisson Richard E RE Raviglione Mario M eng P30 AI094189 AI NIAID NIH HHS United States Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 (...) 26017823 N Engl J Med. 2015 Sep 17;373(12):1178 26376150 N Engl J Med. 2015 Sep 17;373(12):1178 26376151 N Engl J Med. 2015 Sep 17;373(12):1178-9 26376152 N Engl J Med. 2015 Sep 17;373(12):1179 26376153 Antitubercular Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376149 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA5
Latent Mycobacterium tuberculosis Infection. 26376150 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178 10.1056/NEJMc1508223 Jones Jeffrey G JG King Thomas C TC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular (...) Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376150 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA1
Latent Mycobacterium tuberculosis Infection. 26376152 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178-9 10.1056/NEJMc1508223 Tam John K C JK eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular Agents (...) administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376152 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA3
Latent Mycobacterium tuberculosis Infection. 26376153 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1179 10.1056/NEJMc1508223 Flood Jennifer J Scott James J Belknap Robert R eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 (...) Antitubercular Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376153 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA4
Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use – Clinical Correlations Search Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use July 15, 2015 14 min read By: Miguel A. Saldivar, MD Peer Reviewed “Indeterminate.” Many clinicians have expressed (...) frustration when reading this word on a Quantiferon-TB Gold test result. The obligate follow-up question is: what is the next best step? Repeat the Quantiferon? Ignore it altogether and perform a Tuberculin Skin Test (TST) instead? Even worse, what happens when both tests are performed with discordant results? In order to answer some of these questions, this article begins with a very brief overview of Mycobacterium tuberculosis (TB) infection epidemiology. This is followed by a review of the tools
Bedaquiline (Sirturo) - pulmonary multidrug resistant tuberculosis Final Appraisal Recommendation Advice No: 0815 – March 2015 Bedaquiline (Sirturo ® ? ) 100 mg tablets Submission by Janssen-Cilag Ltd Additional note(s): ? AWMSG considered that bedaquiline (Sirturo ® ? ) satisfies the AWMSG criteria for ultra-orphan drug status. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1334), which includes (...) Recommendation of AWMSG Bedaquiline (Sirturo ® ? ) is recommended as an option for use within NHS Wales for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final
Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Since 1990, progress has been made toward global tuberculosis (TB) control, as measured by targets set for 2015. However, TB remains a major threat to health around the world. In 2013, there were an estimated 11 million prevalent cases, and an estimated 9.0 million incident cases occurred globally. Approximately 1.5 million deaths were caused by TB, including 360,000 among people living with HIV. Substantial challenges threaten
Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Before 2007, immigrants and refugees bound for the United States were screened for tuberculosis (TB) by a smear-based algorithm that could not diagnose smear-negative/culture-positive TB. In 2007, the Centers for Disease Control and Prevention implemented a culture-based algorithm.To evaluate the effect of the culture-based